Elevation Oncology announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to EO-3021, a differentiated antibody drug conjugate, ADC, for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction cancer expressing Claudin 18.2 that has progressed on or after prior therapy. “We are delighted to receive Fast Track designation for EO-3021, which marks an encouraging recognition of the unmet medical need in patients with Claudin 18.2-expressing tumors, as well as the potential for EO-3021 to deliver improved therapeutic outcomes,” said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology Announces Preliminary Phase 1 Trial Results
- Elevation Oncology’s EO-3021 shows ‘promising’ Phase 1 anti-tumor results
- Elevation Oncology reports Q2 EPS (18c), consensus (22c)
- Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements